ABSTRACT
The growth and spread of cancer depends as much on the host response to tumor as on the biological characteristics of the tumor itself. This interaction is, at its most, intimate and dynamic within the tumor microenvironment. It is here that the battle is fought that leads to mutual evolution of tumor and host cell phenotypes. Contributing to this evolutionary process are physiological changes distinctive for the tumor microenvironment, such as hypoxia, low nutrient levels, low extracellular pH, and high interstitial fluid pressure. These largely result from the chaotic intratumoral vasculature but are impacted by the nature of the tumor and the inflammatory and wound healing responses that are generated. Numerous infiltrating immune cells, including macrophages, lymphocytes, natural killer cells and dendritic cells infiltrate the tumor, contributing to high levels of growth factors, hormones, and cytokines. We suggest that the integrated interplay between host and tumor factors results in distinct phenotypes that determine the response to therapy as well as tumor behavior.
Targeting the tumor microenvironment to awaken or reawaken immune cells, or to redirect it from a pro-tumor to an anti-tumor state, will require understanding of this phenotype. Current conventional therapies target tumors not tumor cells and clearly affect the host infiltrate and the physiological characteristics of the tumor microenvironment. This may an advantage that has yet to be effectively exploited due to lack of knowledge of existing phenotypes resulting from the tumor-host interactions. The same lack of knowledge impacts outcomes of clinical immunotherapy (IT) trials that have so far not broken through the ceiling of 10% success rate that seems to exist even in melanoma. It seems obvious that more could be achieved by combining therapies that tackle malignancies from multiple angles, with the tumor microenvironment conditioned to support a powerful effector arm generated by IT. The challenge is how to design combination therapies that modify the tumor microenvironment so as to promote immunity and better combat both local and systemic disease. 
OVERVIEW
The immune system faces a tumor on a battlefield that is heavily influenced by multiple aspects of the host response. Disorganized angiogenesis and poor vascular structure seems to be a characteristic of many tumors. This has metabolic consequences and creates an ever-changing microenvironmental landscape with variable areas of (I) high interstitial fluid pressure, (II) low oxygen tension (hypoxia), (III) low extracellular pH and (IV) low nutrient levels. Host leukocyte infiltration into cancers was first noted by Rudolf Virchow in 1863 (1), but its significance is still in question. The abnormal tumor microenvironment generates an inflammatory response with infiltration by macrophages, neutrophils, lymphocytes and fibroblasts that contribute greatly to the tumor milieu. The tumor site becomes to resemble a chronic wound. The result is a mosaic of pro-inflammatory and anti-inflammatory forces with high levels of cytokines, growth factors, and hormones that become a force to be reckoned with systemically as well as locally. These forces sculpt the tumor by selecting cells able to survive and avoid normal regulatory homeostatic forces, including those that are exerted by predatory immune cells. Tumors therefore continually reinvent themselves phenotypically in the face of the host assault and the extreme physiological environment that is created. The host co-evolves with these changes in tumor phenotype and is also continually redefined. The final outcome is often a mutually supportive tumor-host relationship. In this way, the tumor microenvironment provides a platform that is as critical for malignant development as the malignant transformation process itself.
Ehrlich in 1909 (2) was the first to forcibly express the concept that the immune system could recognize tumors and eradicate them. He proposed that "if these (immune) mechanisms did not exist we would expect that carcinomas would appear with enormous frequency". Burnet in 1957 (3) and Thomas in 1959 (4) later formalized this belief as the theory of immune surveillance. Since then, the theory has been extensively and repeatedly modified to account for new findings. It is now acknowledged that, more often than not, cancer patients make detectable antitumor immune responses, both humoral and cell-mediated. In most cases, immune monitoring relies heavily on sampling of patient blood, i.e. measures of the systemic response, because temporal and functional immune profiling within the tumor microenvironment is difficult to perform. However, sufficient studies have been performed to establish that tumor-specific immune responses can occur intratumorally, even without vaccination, which may not be accurately reflected in what is measured in the circulation (5). This, more than anything else, points to the importance of studying immune function within the tumor microenvironment as clearly the keys to devising future immune-based strategies for cancer therapy lie here.
The fact that immune effector cells can find their way into tumors is amply demonstrated by the fact that tumor-infiltrating T cells (TILs) are frequently and increasingly used to identify tumor-associated antigens (TAAs). In many cases TIL lines have been established and used to identify immunodominant epitopes and TAAs for sequencing (6-8). These advances have allowed immunization schedules to be devised that can boost tumorspecific immunity. Most effort has been focused on active immunization for initiating and expanding tumor-specific cytolytic CD8+ T cell (CTL) responses that are often the most potent in causing tumor regression. Disappointingly, although tumor-specific immune responses have been shown to exist in patients that can be boosted systemically and locally, they only rarely translate into clinical responses, although, when they do, dramatic tumor regression can occur.
The infrequency with which clinical responses are made during cancer IT has been ascribed to the existence of multiple tumor escape mechanisms. The list is a long one and will not be dealt with fully here. Some are listed in Table 1 . One important immunological concept, that post-dates Burnett, is that "danger" signals that mature dendritic cells (DC) into powerful antigen presenting cells are required for an immune response to occur (9, 10) ( Figure 1 ). One cause of poor tumor immunity might be the inability of most tumors to generate such "danger" signals. Tumor vaccination strategies typically focus on enhancing this initial priming phase of an immune response. On the other hand, the ability of highly immunogenic, chemicallyinduced murine tumors to grow in the face of strong concomitant immunity has been known for decades and recently human tumor progression in the presence of a massive influx of activated CD8+ T cells has been documented (11). These point to the importance of tumor escape mechanisms that operate at the effector level of immunity (11).
The evidence seems suggest that divergent tumor immune phenotypes could result from the tumor-host interaction. Carcinogenesis-associated mutations and histological type may be influential to the outcome. Some tumor microenvironments may support the generation of immunity, with tumor escape mechanisms that depend heavily on activated proliferation and survival pathways. It is worth remembering that a 1 cm tumor contains 10 9 cells that are capable of dividing every few days and that tumorspecific T cells will be far fewer in number. Given the magnitude of their task, it is not unreasonable to suggest that tumors might grow in the face of robust concomitant immunity. At the other end of the spectrum, some tumor phenotypes might be generated with a highly immunosuppressive microenvironment that present a different therapeutic challenge.
The recent finding that the presence of immune cells in colorectal cancer with a Th1, but not an immunosuppressive or inflammatory, phenotype, as assessed by gene and tissue microarray analysis, together with density and location, was a better predictor than current staging methods (13), speaks to the potential prognostic value of defining the immune cancer phenotype. Whether the immune phenotype has a positive or negative relationship with others, such as those representing a predominance of wound healing, inflammation, hypoxia, and acidosis profiles is of obvious interest as one would expect host profiles to be as predictive of outcome as tumor cell profiles and to be co-regulated. The fact that there are well documented examples of patients undergoing dramatic immune-mediated regression of large tumor burdens gives rise to the belief that if we knew the rules of engagement, immunotherapy would be integrated with other a front-line cancer therapies rather than being considered a last hope, independent therapy, which it tends to be currently.
THE TUMOR MICROENVIRONMENT

3.1.
Physiological influences of the tumor microenvironment Vascular abnormalities in tumors generate spatial and temporal heterogeneity of blood flow and regions of hypoxia, acidity and nutrient depletion. This host response to tumor growth serves as a force of nature to sculpt both. The microenvironment becomes acidic and chronically hypoxic as the oxygen diffusion limit is reached around 100 m away from a blood vessel. Additionally, the chaotic vasculature and high interstitial pressure generate areas that intermittently alternate between periods of hypoxia and reperfusion, changes that are particularly toxic to cells. These extremes in the microenvironment select for cells with mutations in death and survival pathways, with a glycolytic phenotype, and with increased ability to produce angiogenic factors. These activated pathways drive malignant progression and resistance to therapy, as does loss of the sensitizing effect of oxygen that local radiation therapy (RT) and certain forms of chemotherapy (CT) rely on for efficient cell kill (12).
Intratumoral microenvironmental heterogeneity is both considerable and inevitable. Intertumoral heterogeneity compounds this. Together, they place major demands on optimization of cancer treatment. It also makes hazardous attempts to generalize as to these physiological effects within the tumor microenvironment on immune mechanisms. Exceptions are likely to exist to any conclusion that is drawn. However, at the same time the uniqueness of the tumor microenvironment is an "Achilles Heel" that can be exploited for therapeutic benefit and its modifying it with a view to enhancing tumor immunity is a concept that is worth exploring.
Tumor-associated immune cells 3.2.1. Tumor-infiltrating lymphocytes (TILs)
The presence of a large number of TIL in a tumor microenvironment is often considered an indication of immune host-tumor interactions, although only a small percent may be tumor-specific. Much is known about the coordinated participation of selectins, chemokines and integrins in the multistep process that recruits lymphocytes from the circulation into normal tissues. Far less is known about the mechanisms of lymphocyte entry into tumor tissue, but this may dictate TIL phenotype and specificity. The fact that tumors often express chemokines (13, 14) and receptors (13, 15) 
Inhibitory T cell populations
Berendt and North (50) first applied the T suppressor cell findings of Gershon (54) to cancer when they found that infusion of splenic T cells from tumorbearing donors inhibited concomitant immunity in a mouse mode. Twenty years later, the concept has been resurrected in the form of a small subset of CD4+ cells regulatory T cells (T reg 58) , and in human metastatic melanoma lymph nodes (59) .
The mechanism of T reg recruitment to the tumor site is poorly understood. Recently, Ghiringhelli et al. showed a subset of immature myeloid DC differentiates into TGF-beta producing cells that stimulate CD4+CD25+ T reg proliferation in draining lymph node of colon cancer bearing mice (60). Curiel et al. (58) reported that the chemokine CCL22 produced by ovarian tumor cells and tumor associated macrophages (TAMs) mediate trafficking of T reg to the tumor mass. Specific recruitment of T reg into tumors may therefore be a powerful mechanism of immune escape for tumors.
Other mechanisms could down-regulate T cell responses in the tumor microenvironment. For example, while B7.1 and B7.2 (CD80 and CD86) molecules are important co-stimulatory molecules for T cell activation (61), a third member of the B7 family, B7-H1, seems to have a negative regulatory effect through IL-10 secretion (62) . A subset of myeloid DCs in the tumor microenvironment expresses B7-H1 (63) and T reg expresses PD-1, the ligand for B7-H1 (64). B7-H4 (B7X or B7S1) has recently been identified as another negative regulator of T cell responses that is expressed largely by TAMs (65) . Overexpression of such molecules in the tumor microenvironment might serve as selective targets for intervention.
Tumor infiltrating dendritic cells (TIDCs) and TAA presentation
DCs are the most potent antigen presenting cells known, but belong to several lineages. TIDCs of the Langerhans, plasmacytoid (pDCs) and myeloid (mDCs) subtypes have been reported in human tumors (66) (67) (68) (69) (70) . The extent of infiltration is variable and dependent on the tumor type and stage (67, 68) , as is their precise location and their stage of maturation. One study reported that DCs were located at the invasion edge of the papillary thyroid carcinoma while TAMs were evenly distributed throughout the tumor (71). The mechanisms by which DCs traffick to the tumor site are poorly understood. Chemokine ligands 2, 3, 5, 7 and 8 and their receptors have been implicated (71-73). However, to trigger immunity, DCs need to reach the secondary lymphoid organs and present antigen to lymphocytes (Figure 1 ). This migration minimally involves interaction between chemokine receptor CCR7 expressed by DCs and the ligand CCL21 by the lymphatic endothelium (68) .
The functional status of TIDCs is more important than their mere presence (65) . Maturation of DCs is required for antigen presentation while immature DCs generally are thought to induce tolerance (74) (Figure 1 ).
Mature mDC (CD11a+,CD11c+,CD14-,HLA-DR+) are reportedly rare in human ovarian (69) , breast (75, 76) , prostate (77) and renal cell carcinoma (78) . High levels of suppressive cytokines and growth factors in the tumor microenvironment may be a major cause of defective mDC maturation and differentiation. COX-2 and VEGF can suppress mDC maturation and function (79-81) while IL-6 and M-CSF can direct monocytes away from TIDCs towards TAM differentiation (82) . In addition, mDCs in breast tumor and lymph nodes in melanoma, breast, colon, lung and pancreatic cancer patients express indoleamine-2,3-deoxygenase (IDO) that catalyzes oxidation of tryptophan (83) and can suppress T cell proliferation and cause their death by tryptophan depletion. There are few studies that assess intratumoral DCs at the functional level but antigen presenting capacity of cells from within an immunogenic murine fibrosarcoma was intact and the immunopotentiating potential of TAMs was considerable (84, 85) .
In contrast to mDCs, pDCs (86) and vascular DCs (87) , which can stimulate angiogenesis, are abundant, at least in ovarian tumors. pDCs can induce angiogenesis through production of TNF-alpha and IL-8 (86) and, in the absence of appropriate stimulation in tumor microenvironment, can promote development of regulatory CD8 T cells (88) and a Th2 response (89).
Tumor-associated macrophages (TAMs)
TAMs are present in substantial, though variable, numbers (10%-65%) in different tumors (90, 91) . Obviously, they have a major impact on gene expression profiles, functional imaging features, and many characteristics often ascribed to "tumors". TAMs are most often found in the tumor margin but in some cancers, such as breast (92) and endometrial cancers (93) they accumulate around necrotic foci, and in others they may be distributed throughout the tumor. In breast cancers, Leek et al. (94) showed that the degree of necrosis was correlated with both focal TAM infiltration and high vascular density.
Any one transplanted tumor cell line maintains a remarkably constant proportion of TAMs after the first few in vivo passes (95) , indicating that tumor-derived products, most likely cytokines such as the colony stimulating factors GM-CSF and M-CSF, determine the number and state of functional activation of these cells. TAMs demonstrate considerable heterogeneity in size, phenotype, and function within any tumor (96) and are major sources of a wide range of intratumoral cytotoxic mediators, cytokines, growth factors, angiogenic factors and proteases (97) . Many of the vascular effects within the tumor microenvironment are mediated or influenced by TAMs. They respond to hypoxia with production of hypoxiainducible factor (HIF) (98) .
There has been considerable controversy as to the role TAMs play in tumor progression. One way this might be rationalized is by considering whether they have predominantly a type 1 (M1) or a type 2 (M2) phenotype (see reviews by (99, 100)) ( Figure 2 ). The former are better able to kill tumor cells, present antigen, and produce immune-stimulatory cytokines, while the latter promote angiogenesis, tumor growth and metastasis, and suppress T cell function. It will be important to understand this yinyang balance if immune intervention strategies are to be successful. It seems reasonable to suggest that over the long, prolonged battle for supremacy between the tumor and host there is likely to be selection for tumors that enlist the help of M2 TAMs to grow, however the ability of tumors to grow in the face of robust immunity suggests that M1 TAM phenotypes will also be present.
The M2 phenotype may be promoted by tumorderived factors such as the interleukins IL-4, IL-6, IL-10, transforming growth factor beta (TGF-beta , PGE2, and M-CSF (101) . M2 TAMs in turn assist the tumor by producing high levels of similar cytokines and prostaglandins, and factors such as vascular endothelial growth factor (VEGF) that promote angiogenesis (102) . M2 TAMs suppress T (103) and NK (104) cell activity (105, 106). At the other end of the spectrum, M1 TAMs may be generated by certain tumor phenotypes that are more immunosupportive, and by TAA-directed Th1 and CTL responses that release IFN-gamma and IL-3 to activate TAMs. Under these circumstances, tumors presumably rely on a different battery of escape mechanisms such as increased resistance to cytotoxicity or increased proliferation.
The cytostatic and cytolytic actions of M1 TAMs can be mediated either by direct contact with target cells or release of soluble mediators. Two major mediators are TNF-alpha and nitric oxide (NO). Since the action of TNFalpha is dependent on the generation of hydroxyl radicals, the cytotoxic ability of this population would be diminished in hypoxic areas (107) (108) (109) . In contrast, hypoxia can enhance NO production (110) , which at high levels can inhibit tumor cell proliferation and enhance cell death (111) . On the other hand, at lower concentrations, NO will protect tumor cells from apoptosis (112, 113) , suppress immune responses (114) , stimulate angiogenesis (115), and increase tumor blood flow (116, 117). The balance of inducible nitric oxide synthase (iNOS) to negative regulators of this pathway is therefore likely to be critical to outcome. A major negative regulator of NO is arginase, which can be produced in large amounts by M2 TAMs. Depletion of L-arginine by arginase can suppress NOmediated macrophage cytotoxicity and T cell function (121), while polyamines and other products of the arginase pathway are growth factors for tumor cells, and depletion of L-arginine by arginase can stimulate tumor cell proliferation (118). Production of iNOS or arginase is therefore one expression of their M1 or M2 phenotype of TAMs and their ability to hinder or promote tumor growth ( Figure 3) . A major issue that is critical to planning cancer treatments with the best therapeutic outcome is the extent to which TAMs can switch their phenotype from M2 to M1 in response to stimuli, such as immune activation (127) and whether this requires a fresh host cell infiltrate.
It seems reasonable to suggest that over the long, prolonged battle for supremacy between the tumor and host, some tumors will be selected that enlist help from M2 Figure 2 . Cartoon depicting the tumor microenvironment. Extreme physiological conditions in the tumor microenvironment such as vascular abnormalities lead to acidity and chronic hypoxia. This ultimately selects for a resistant cellular phenotype that drives malignant progression and immune escape, which is exemplified by chronic inflammation, cytokine imbalance favoring T helper type 2 (Th2), dendritic cell (DC) dysfunction, dendritic cell subset imbalance, suboptimal tumor-associated antigen presentation, insufficient effector T cell priming, T cell receptor dysfunction, suppressive T regulatory (T reg ) cells and tumor-associated macrophages (TAMs) and T cell subset imbalance.
TAMs to escape immunity and grow. This phenotype may be promoted by tumor-derived factors such as the interleukins IL-4, IL-6, IL-10, transforming growth factor beta (TGF-beta , PGE2, and M-CSF (101) . M2 TAMs in turn assist the tumor by producing high levels of similar cytokines and prostaglandins, and factors such as vascular endothelial growth factor (VEGF) that promote angiogenesis (102) . M2 TAMs suppress T (103) and NK (104) cell activity (105, 106). At the other end of the spectrum, M1 TAMs may be generated by certain tumor phenotypes that are more immunosupportive, with the tumors relying on other escape mechanisms such as increased resistance to cytotoxicity or increased proliferation. A major issue that is critical to planning cancer treatments aimed at achieving the best therapeutic outcome is whether or not TAMs switch their phenotype in response to certain specific stimuli, such as immune activation (119).
The yin-yang of immune profiles in cancer
The yin-yang balance observed in TAM phenotypes yields cytokine profiles that have both pro-and anti-inflammatory components, although one tends to predominate. For example, in breast carcinoma, TNF-alpha is highly expressed (120-122) that could be cytotoxic to tumor cells but more often may select for TNF-resistant cells and even promote tumor cell proliferation (123), angiogenesis, and metastasis (121, 122). A similar argument can be made for IL-1 and other pro-inflammatory cytokines that are also frequently overexpressed in breast (120), squamous cell (124) and head and neck cancer (125).
In contrast to expression of pro-inflammatory cytokines, immunosuppressive cytokines, in particular IL-10 and TGF-beta (126), are also often elevated in advanced tumors and correlate with a poor clinical prognosis (65, (127) (128) (129) . Both are generally anti-proliferative for many cell types, including T cells, but many tumor cells have lost the ability to respond to these cytokines by mutation (130, 131). In contrast, T cell expansion and activation (142), LAK cell activity (143) and NK cell function (144) are inhibited while T reg cell expansion is promoted (132). IL-10 also blocks DC-mediated priming of CD8+ T cells (133) and DC recruitment (134). Production of these cytokines may be stimulated by COX2 and prostaglandins, which many human tumors express at high levels (82, (135) (136) (137) . Angiogenic cytokines, such as VEGF and erythropoietin, seem to be favored by such an environment, in addition to being induced by hypoxia (138).
Overall, the data suggest that the tumor microenvironment can present many profiles that might be viewed as ranging from being highly immunosuppressive to immunosupportive (Figure 2 ). These might be linked to characteristic physiologic profiles, such as mean vessel density, acidosis, hypoxia, extent of nutrient deprivation, etc. Defining these profiles is still in its infancy but the concept is an important one since such profiles may reflect the extent of immune recognition and point to the likelihood of immunity being involved in response to conventional therapies. They also might offer targets for novel intervention with the aim of changing the phenotype of the tumor microenvironment to be more immunosupportive, which may be an absolute requirement for effective IT either deliberately generated or passively acquired during other therapies.
MODIFYING THE TUMOR MICROENVIRONMENT TO ENHANCE TUMOR IMMUNITY
Conventional therapies affect the tumor microenvironment
It is axiomatic that therapy aimed at tumors targets the tumor microenvironment and the host cell infiltrate as well as the tumor cells. Given that the tumor microenvironment may range from immunosuppressive to immunosupportive leads to questions as to how conventional treatments impact these profiles and viceversa, how conventional treatments might be optimized to bring out the best in the immune system, how IT might best be integrated into a conventional schedule, and how the tumor microenvironment might be modified to support the development of tumor immunity.
It should be noted that the use of preclinical transplanted tumor models can easily mislead investigators into thinking that conventional treatments enhance immunity. In mice, immunogenic tumors grow in the face of concomitant immunity, they are easier to cure by conventional RT or CT than non-immunogenic tumors, and if complete regression occurs, or if tumor is surgically removed, a state of systemic immunity can easily be demonstrated. In these situations, therapy most likely unmasks the potential of the immune system to combat tumor growth, as opposed to acting as a positive stimulus to generate immunity. Most human tumors that arise spontaneously are only weakly immunogenic and have a wide range of phenotypes that may not be well represented by a single transplantable tumor model. The important questions are whether RT or CT can create an immunosupportive from an immunosuppressive tumor microenvironment, under what conditions, and whether additional manipulations are needed to better translate therapy-induced cell death into the generation of immunity.
Radiation therapy
Traditionally, ionizing radiation has been thought of as a "silent" killer, in that radiation-induced cell death does not readily translate into tumor immunity. This is somewhat surprising since radiation often induces immunologically 'loud' necrotic cell death, in addition to apoptosis (139, 140). The presumed liberation of TAA and the release of nucleic acids that follow RT might be expected to have powerful immune activating properties (141-143), which may favor antigen capture and maturation of DCs (144) . Perhaps the most exciting hypothetical possibility is that RT might broaden the spectrum of TAA epitopes that are recognized by the immune system, either by altering the molecules themselves so as to provide more helper recognition or the amount of rare TAAs released at any one time. There has also been much recent discussion as to the importance of RT in facilitating antigen presentation by induced phenotypic changes on irradiated tumor cells and DCs. For example, there is ample evidence for RT-induced up-regulation of molecules, such as MHC class I and II, TAA, the co-stimulatory molecule CD80 and CD86, and the expression of members of the death TNF receptor family and their ligands (145-150) (McBride unpublished). Importantly, in vivo RT has been shown to up-regulate MHC class I expression on the leading edge of invasive glioma cells in mice (151) . It is easy to see how anti-tumor immunity and tumor control might be enhanced by these mechanisms (152) , but it seems that up-regulation in expression of all molecules is not a universal phenomenon and further work is needed to elucidate the mechanisms involved and their relevance. Also, there is no consensus as to what the best radiation dose or scheduling might be or even the circumstances, if any, under which this would be effective.
Another potentially immunologically positive feature of irradiation is that it causes recurring waves of cytokines, chemokines and growth factors, most prominently TNF-alpha, IL-1, TGF-beta, and EGF (153) (154) (155) (156) (157) (158) (159) , that might be expected to act as 'danger' signals to activate DCs to present TAA (160) . The synergy seen between RT and various IT approaches in achieving better tumor control in mice encourages enthusiasm for this view (148, 161-164). As mentioned above, the critical issue is whether RT acts as an immune adjuvant in these situations or simply unmasks existing immunity. Irradiated tumor cell vaccines made from most spontaneous mouse tumors are unable to generate a state of protective immunity (165, 166) (the classical definition of "non-immunogenic"), suggesting that irradiation does not readily confer immunogenicity on tumors and there is little evidence that release of debris from non-immunogenic tumors in vivo caused by local RT translates into immune activation (167, Liao unpublished). By analogy, one might expect little immune activation following RT of human cancer. On the other hand, basic parameters such as the optimal radiation dose, dose rate, and fractionation schema have not been extensively investigated and could have an impact.
Unmasking of an existing immune state by RT is, of course, a potentially positive contribution providing such a state exists or can be generated. In addition, the ability of RT to shrinks tumor bulk dramatically and slow the rate of tumor cell proliferation could be enough to give the immune system an advantage (168) . Irradiation may also increase trafficking of cells into tumor, as it does for normal tissues as a result of increased expression of adhesion molecules on the surface of endothelial cells involved in extravasation, such as ICAM-1, E-selectin, VCAM-1 and CD31 (169, 170) (171) (172) (173) . In tumors, the promotion of host cell trafficking may be offset by radiation damage to endothelial cells and the tortuous tumor vessels and defective angiogenesis, but the overall outcome may still be in favor of tumor control (174) (175) (176) , as has been shown in some mouse tumor models (152) . This may be a result of RT-induced decreases in interstitial fluid pressure, remodeling of the extracellular matrix, tumor re-oxygenation, and/or changes in vascular flow more than radiation-induced changes in adhesion molecules (177) (178) (179) (180) (181) .
A particularly important question is whether RT can make an immunosuppressive intratumoral environment into an immunosupportive one. There is little data on this but at least one study suggests otherwise. Tsai et al. (182) showed that single and fractionated radiation doses in a murine prostate cancer model did not generate much TNF-alpha, which may polarize TAMs towards a M1 inflammatory phenotype with predominantly tumoricidal activities (183) , but simply accentuated the production of arginase and COX-2 and the generally immunosuppressive and pro-tumor microenvironment. There was little increase in anti-tumor immunity following RT. This is clearly not the final word on this important subject.
Having said that, RT, because it is a powerful cytotoxic modality, will directly and indirectly affect immune cell survival and function within the tumor microenvironment, which will have immunomodulatory effects. Different intrinsic radiosensitivities will shape the balance of intratumoral TIL subsets. In general, memory T and NK cells are relatively radioresistant when compared to B cells and naïve T cells (184, 185) . Importantly, North and colleagues (186) demonstrated, in murine models, that sublethal whole body gamma-irradiation led to partial or complete tumor regression in immuno-competent but not in immuno-incompetent animals. They argued that radiationinduced elimination of suppressor T cells or their precursors shifted the immune-balance in favor of effector T cells (187-189). Again, tumor immunogenicity may contribute an immunosupportive milieu to these findings and concomitant immunity may be simply unmasked. However, Yu has shown that localized depletion of suppressive T cells can translate into tumor rejection (190) . Whether this is as effective as whole body irradiation has yet to be evaluated but it argues that RT may be a useful therapeutic immune adjuvant even at low doses. Whole body irradiation may have an additional advantage that it would enrich for systemic T memory cells and allow space for their selective lymphocyte expansion, as it does in cell transfer studies.
Macrophages and DCs tend to be radioresistant but may be functionally affected by RT. Irradiation of DCs in vitro can inhibit their ability to endogenously process and present MART-1 TAA to T cells and to generate protective tumor immunity (191) , }, which has very evident clinical implications. Interestingly, cross-presentation of TAA was enhanced after RT and this may be a positive aspect of RT that could be further exploited.
One rationale for combining IT with RT is that IT may be able to increase the likelihood of achieving local tumor control with RT while eliminating disease outside the field by immune mechanisms. In spite of all the caveats and the lack of rigorous mechanistic evidence on certain critical issues, numerous in vivo studies have demonstrated that local RT can enhance the systemic effect of IT. These studies have utilized mainly DC-based and/or viral vaccines and/or local or systemic GM-CSF, IL-2 and IL-3 therapy (150, 162-164, 192, 193) (167, 194, 195) . For example, Lumniczky et al. (161) showed that administration of vaccines producing GM-CSF, IL-4, or IL-12 in combination with local RT resulted in >80% cure of murine brain tumors. Others (167, (196) (197) (198) (196) . It is not surprising that approaches integrating IT with local RT of prostate cancer, pancreatic cancer, melanoma, glioblastoma multiforme, non-small cell lung cancer have entered phase I and II of clinical testing under NCI approval (199, www.clinicaltrials.gov).
The impact of RT on immune defenses is obviously complex and multifactorial but there are many facets of relevance to the tumor microenvironment that are worthy of further investigation. In this age of combination therapies, it is however also necessary to consider the impact CT might have on such responses and how its effects on immune modulation in the tumor microenvironment might differ from those of RT. .
Chemotherapy
Similar to RT, CT appears to augment IT in ways that are difficult to explain by a simple de-bulking hypothesis alone (reviewed in (200) (201) (202) ). General and selective lymphopenias are often manifest that may allow for the selective recovery of tumor-specific immune machinery, especially when used in conjunction with vaccination or adoptive cell transfer (201, 203) . As for RT, this concept is based, in part, on the old observations that the administration of cyclophosphamide in rodents and indeed in humans depletes circulating T regulatory cells and famously counteracts peripheral tolerance (187, [204] [205] [206] [207] [208] . Conversely, cyclophosphamide also may favor memory T cell proliferation, possibly through controlling T cell growth factors and iNOS expression (209) (210) (211) . The nucleoside analogue Gemcitabine is also immune modulatory. It selectively reduces B cells and myeloid suppressor cells in tumor-bearing mice while increasing the anti-tumor activity of CD8 T cells and NK cells (212, 213). Importantly, while resculpting the T cell balance, these cytotoxic drugs do not appear to greatly reduce the frequency of tumor-specific T cells (200) . In any event, the relative resistance of memory T cells to CT seems a consistent finding that could be exploited, as it could for RT.
Many cytotoxic drugs can prime the local tumor microenvironment to facilitate anti-tumor immune attack. Gemcitabine, increases T cell infiltration into solid tumors in rodents, while cyclophosphamide does not (214, 215). Docetaxel on the other hand greatly compromises the motility of DCs, especially at very low doses (216). Whether or not this depends on drug-induced changes in the cytokine milieu or is due to vascular changes is not clear. In fact, endothelial proliferation and tumor angiogenesis are inhibited by many cytotoxic drugs, especially when given in metronomic doses (217) (218) (219) , although agents such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) that directly target the vasculature can also have an immune-modulatory component as they can increase cell trafficking to the tumor site (220) . In general, cancer chemotherapeutic drugs that are currently in the clinic vary considerably regarding their modes of antitumor action and there is no reason to believe that this isn't also true for effects they might have on the immune response.
Some chemotherapeutic drugs also modify events at the immunological synapse. Tumor cell death will liberate potential antigenic peptides for cross presentation (221) . Gemcitabine, for example, has this immune priming effect (222) . Taxol is particularly intriguing in that it appears to activate macrophages and DCs through toll-like receptors to produce IL-12 and hence could alter the Th1/2 balance in the tumor microenvironment, while also being able to suppress lymphocyte proliferation (223) (224) (225) . Improved tumor-antigen presentation and T cell activation due to drug-induced expression of MHC and co-stimulatory molecules on tumor and DCs are not uncommon. They have been reported in preclinical studies for 5-aza-2'-deoxycytidine, 5-fluorouracil, melphalan, chlorambucil, cytosine arabinoside and bryostatin (144, (226) (227) (228) (229) (230) (231) . There is substantial evidence that CT can also enhance the effector arm of the immune response by 'weakening' the target. Drugs such as 5-fluorouracil, dacabazine, cisplatin and cytosine arabinoside sensitize tumor cells to antigenspecific CTL-mediated lysis by enhancing fas-dependent and -independent pathways (230, (232) (233) (234) (235) .
Clearly, these cytotoxic drugs could shape an immune-mediated tumor rejection mechanism either acting through modification of the tumor microenvironment or by systemic action, making a strong case for combining CT with IT. Ultimately, the combination chosen, and how timing and dosing are applied will have to be carefully assessed in order not to compromise the efficacy of each individual modality alone. For example, in mice, the combination of cyclophosphamide, doxorubicin and taxol can enhance the anti-tumor potency of a GM-CSF vaccine, but only when given in a specific sequence, while cisplatin remains ineffective (236) . IL-12 can delay the growth of murine tumors only when given after taxol treatment, while simultaneous administration of drug and cytokine can not (237) . An increasingly utilized way of combining CT and IT in clinical cancer trials is myeloablative/lymphodepleting CT followed by autologous stem cell transplant and low-dose CT, in combination with various biological therapies (IL-2 or GM-CSF-based, cellular adoptive IT, with or without vaccine therapy with autologous DCs), or alternatively lower CT doses combined with similar vaccines. These strategies are currently being tested for patients with lymphoma and leukemia, as well as cancer of the breast, prostate, lung, testis, kidney, rectum, ovaries, multiple myeloma, and, of course, melanoma (www.clinicaltrials.gov).
Surgery
The influence of surgery on immune function has been largely examined from the immunosuppressive aspect consequent to trauma. Chemotaxis, serum cytokine levels, and cellular activities have been reported to be severely suppressed, and this could increase the chance for metastases formation, although there are few reports on the impact of surgically-induced inflammation on presentation of TAA for tumor-specific immunity. The bigger the surgical incision is, the more pronounced the immune suppression will be. The ongoing development of minimally invasive techniques, such as laparoscopy, may provide the surgeon with an alternative that helps preserve immune activity (238) . This may be especially important for combating postoperative or residual disease. It is not clear if innate and adaptive responses are equally affected (239-243), but in either event, the effects of surgery on the immune system may need to be taken into account when used in conjunction with other modalities. The jury is still out on whether or not the immunological benefits of keyhole surgery outweigh potentially serious adverse effects, such as port wound tumors (244).
Specific targeting of the tumor microenvironment
It is almost axiomatic that cytotoxic agents, including RT and CT, will affect hypoxic status and acidosis in the tumor microenvironment, simply by causing cell death. They will also affect immune function, directly through affecting the balance and activation of host cells, as well as indirectly through altering the tumor microenvironment. These effects could be critical to the outcome of conventional treatment but their influence is difficult to assess and may depend upon the extent of cell depletion. Conventional cytotoxic therapies roil the tumor microenvironment non-specifically, but new biological targeting agents are coming online that promise more selective control, although their lack of cytotoxicity generally means that these will generally be used in conjunction with conventional treatments
Hypoxia and tumor acidosis
Various strategies have been used to target hypoxia itself or the biological responses to it, while others have been found to do it passively. Approaches to alter hypoxia include hyperbaric gas inhalation, transfusions, NSAIDs, mild hyperthermia, and VEGF blockade (245, 246) . In addition, HIF-1 may also be destabilized and/or inhibited either directly or through targeting Hsp90, topoisomerase I, or COX-2 (247-253). There have also been considerable efforts to screen for novel HIF-1 pharmacological inhibitors (254) (255) (256) (257) . Some of these compounds exhibited beneficial effects in murine tumor models and have entered clinical trials (151, (258) (259) (260) . These might be expected to affect angiogenesis through VEGF inhibition, but also to have unexpected effects on the immune system.
Tight regulation of HIF-1 is essential for the normal development of many cells and tissues, including lymphocytes and monocytes, as well as for the expression of inflammation (261) (262) (263) (264) (265) (266) (267) (268) . Targeting of HIF-1 in attempts to eliminate hypoxic cells or inhibit their role in angiogenesis may therefore have the incidental effect of enhancing general and tumor-specific immune function. This may explain why antisense to HIF-1 alpha caused a murine tumor to regress in a NK cell dependent fashion (269) . The number of TAMs with an immune-suppressive phenotype that typically develop under low oxygen tension may also decrease (270) and their energy balance alter, which can translate into impairment in motility, invasiveness, adhesion and antibacterial function (267, 271) . Targeting hypoxia may also restore CD80 expression and possibly MCP-1 and MMP-9 production by macrophages, which should aid co-stimulation and leukocyte recruitment (272) (273) (274) . Based on studies with ischemia-reperfusion and systemic hypoxia, restoring oxygenation may be expected to enhance adhesion and migration of DC and NK cells and the activation and survival of TILs (263, (275) (276) (277) .
Ultimately, targeting hypoxia may also change tumor acidosis, although the link between two phenomena is not entirely clear (278) (279) (280) . Acidosis may be counteracted indirectly through targeting hypoxia by temporal O 2 conditioning of tumors or by inhibition of the hypoxia-inducible carbonic anhydrase (43, 281). Strategies that modify metabolism or ion pumps to transiently increase or decrease acidosis have been tested in animal tumor models and clearly enhance the toxicity of certain cytotoxic drugs (282) . However, by and large, the issue of how targeting acidosis will shape the tumor microenvironment and tumor immunity has not been addressed. Based on what we know about immune function and the importance of extracellular pH, acidosis intervention may enhance lymphocyte proliferation and cytotoxicity, chemotaxis of leukocytes, and macrophage function, although the antigen-presentation skills of DCs might be compromised by such approaches (283) (284) (285) (286) (287) . Perhaps the introduction of vascular targeting agents into the clinic will put more urgency into these studies.
Vasculature and angiogenesis
Targeting either angiogenesis or the established vasculature in tumors has been the focus of much recent attention and both have profound effects on the tumor microenvironment. They are conceptually different approaches as the former aims to prevent new vasculature growth while the latter aims to disrupt existing tumor vasculature to cause necrosis. Several agents are currently undergoing clinical evaluation, especially as part of multimodality treatments (reviewed in (288) ). The most clinically advanced is the FDA-approved humanized monoclonal antibody against VEGF-A, Avastin (Bevacizumab) (289, 290 ).
Avastin appears paradoxically to cause transient vascular normalization, reduced vascular permeability and reduction in interstitial fluid pressure (291) . This may be because VEGF is also vascular permeability factor. Targeting VEGF enhances drug delivery and there is no reason to believe that it shouldn't also improve immune cell access, provided normalization persists. Sun et al. (292) showed that the potent anti-angiogenic factor angiostatin in combination with IT involving T cell costimulation caused murine tumor rejection, whereas either therapy alone did not. The vascular disrupting agent DMXAA increased the traffic of macrophages and lymphocytes to the tumor site ultimately leading to the generation of an anti-tumor immune response (220) . On the other hand, vascular targeting by anti-VEGF may inhibit TAMs, since they are its major source and respond to it with migration and activation (293) (294) (295) . This need not necessarily be a bad thing for cancer therapy if the TAMs exhibit a M2 phenotype (296, 297) . There is yet another dimension to vascular targeting, in that cells of haematopoeitic origin appear to contribute if not initiate tumor spreading through expression of VEGFR1. An elegant study by Kaplan and colleagues showed that bone marrow progenitor cells expressing this receptor create a pre-metastatic niche long before the tumor cells arrive (298) .
One particularly novel strategy to target the endothelium is by vaccination. For example, at least in preclinical models (299), immunization with VEGFR2-pulsed DCs, or VEGFR2-derived peptides, or VEGFR2-based DNA vaccines elicited humoral and/or cell-mediated immune toxicities towards tumor endothelial cells that prevented tumor angiogenesis and tumor growth and in the last case slowed the growth of established murine tumors (300) (301) (302) (303) . Humanized A2/K b transgenic mice responded to VEGFR2 peptide vaccination and had better tumor control (304) . The same group demonstrated that responses could be generated in cancer patients, at least ex vivo. Tumor control may be further increased by targeting both vasculature-associated antigens and TAAs (305).
Extracellular matrix and fibroblasts
According to traditional belief, tumor angiogenesis, tumor invasion and even early tumorigenesis are not possible until the extracellular matrix (ECM) and the basement membrane are degraded. Consequently, inhibiting the enzymes that are involved in this remodeling process such as matrix metalloproteases (MMPs), cysteine and serine proteases, and heparanase may improve tumor control (reviewed in (288) ). The unfortunate failure of some of the 1 st and 2 nd generation broad-spectrum MMP inhibitors in the clinic made apparent the spatial and temporal complexity of the ECM balance associated with tumorigenesis (reviewed in (306, 307) ). However, since proteases are so intimately involved with molecules such as TNF-alpha, IL-1beta and TGF-beta, chemokines, and adhesion molecules, chemotaxis and immunity are likely to be affected by their inhibition (307) (308) (309) . Tissue inhibitors of MMPs (TIMP-1) inhibited the migration of immature dendritic cells and TIMPs are therefore possible targets for intervention (310) . Although the relationship may be circumstantial, skin cancer prevention in mice with a polyphenolic botanical supplement both inhibited MMP2 and MMP9 and increased cytotoxic T cell numbers (311) . TIMP-1 also restored IL-2-dependent proliferation of TILs, at least ex vivo (312) . Any structural modification of the ECM can potentially lead to the activation of cryptic ECM activities, so-called matricryptic sites within ECM molecules (313, 314) that encourage adaptive immunity.
Antibody-mediated or pharmacological targeting of integrins that maintain the communication between cells and the ECM proteins have also shown promise in preclinical studies and are undergoing evaluation in the clinic (315) . Strategies that selectively target activated fibroblasts or their products within the ECM framework are under development and preliminary data are encouraging. These approaches are based on the fact that fibroblasts can act as tumor suppressors under normal condition, but alter their phenotype to an activated one that enhances epithelial transformation and migration in established tumors (288) . All in all, although our knowledge of how ECM targeting will affect tumor immunity is currently very limited, there is evidence that ECM modulation is likely to have multiple effects on tumor immunity.
Counteracting immune suppression in the tumor microenvironment 4.3.1. Inflammation, cytokines and "danger"
A relationship between many cancers and chronic inflammation has long been suggested, and is perhaps best exemplified in the tumor preventative potential of nonsteroidal anti-inflammatory drugs (316) (317) (318) (319) (320) (321) . Such treatments might be expected to enhance tumor immunity but it is still not clear what is the optimal inflammatory profile to generate such responses. This is even more important if the cytokine balance is to be therapeutically skewed from being immunosuppressive to being immunosupportive, as may already be being achieved with some strategies. For example, preclinical studies with IL-2 gene therapy along with RT has shown efficacy that may be due to decreased intratumoral hypoxia (322) , and might be expected to be immunosupportive. IL-3 gene therapy also decreases hypoxia in experimental tumors (McBride, unpublished) and is immune enhancing. Perhaps this is why cytokine gene therapy can be particularly effective in combination with RT. On the other hand, essentially any therapy will alter tumor hypoxia. Whether this is sufficient to change the intratumoral milieu into one that is immunosupportive is not clear. Perhaps local delivery of cytokine mediators may be required to change the intratumoral profile and for highly toxic agents such as TNF-alpha this may be the only route possible, and it has shown efficacy in patients with sarcoma (323, 324) . It would be of interest to know how tumor immunity is affected.
Anti-inflammatory drugs, especially the new generation of selective, yet controversial COX-2 inhibitors also show promise in systemic targeting of the chronic inflammatory profile. Pharmacological targeting of COX-2 appears to counteract some tumor escape mechanism in vivo such as a suppressive cytokine milieu, suppressed DC function, preferential Th2 response, limited T cell proliferation, MHC-mediated NK cytotoxicity and IDO expression (325) (326) (327) (328) . Not surprisingly, COX-2 inhibitors such as celecoxib or rofecoxib can boost the efficacy of cancer vaccines by enhancing tumor-specific CTLs in mice (329, 330) . When thinking further upstream of inflammatory signaling cascades, NF-kappaB -the master regulator is certainly an attractive target (331, 332). Mouse colon cancer cells expressing a super repressor of NFkappaB, for example, are unable to form inflammationinduced lung metastasis (333) . Taking this further, reducing inflammation and its mediators may also dampen HIF-1 activity, which in itself would be a desirable 'side' effect (see above, (266)).
Dendritic cell and macrophage function and subsets
Numerous IT trials apply dendritic cell vaccines with TAAs in the form of DNA, peptides, proteins or in viral vectors, in attempts to boost immune responses to cancer. Others use gene therapy approaches to modify immunity within the tumor environment. The cytokines GM-CSF and IL-3 are thought to, in part, bring about some of their immune enhancing effects through generating DCs (173) (174) (175) . Other approaches target using co-stimulator molecules such as B7.1 and B7.2 (334). Melanoma patients subjected to intralesional vaccinia virus vector expressing B7.1 developed systemic T cell responses against tumor antigens that in some cases translated into partial responses or stabilization and prolonged survival (335) . That there is room for improvement was recently shown in mice whereby a vaccination with 4-1BBL in addition to B7.1 led to even higher levels of tumor-specific T cells (336) . Whether this approach is better than systemic administration is not clear and may depend on the strategy. For example, blocking chemokines or receptors involved in the recruitment of immune-suppressive DC subsets such as plasmacytoid DCs and myeloid suppressor DCs would suggest an intratumoral approach, as would use of AMD3100, which is a CXCR4 antagonist that can counteract the chemorepulsion of T cells associated with CXCL12 expression by tumor (337).
T regulatory cells and T cell imbalance
Another approach to counter T cell anergy is aimed at the effector arm of immunity (338) . Of particular interest is the recent use of adoptive transfer of T cells genetically modified to express monoclonal TCR with specificity for a TAA epitope in lymphodepleted patients (339) . Such studies are easily adapted to imaging of the adoptively transferred cells and examination of their ability to localize to the tumor and assessing the effects of therapies on such infiltrates are likely to give valuable information on how to modify the tumor microenvironment to optimize IT. In some of these adoptive transfer experiments, depletion of T reg s with antibodies, which have been shown to enhance anti-tumor responses (340) (341) (342) (343) , may be an essential element. How necessary this will prove to be will have to be determined. Metabolic intervention with production of IDO, the enzyme responsible for tryptophan deprivation and hence T cell anergy or death, improved tumor control in mice in a T cell dependent fashion (344) . Even more promising is IDO inhibition when used in combination with cytotoxic treatments. Simultaneous targeting of IDO by 1-methyl-tryptophan (1MT) with paxlitaxel, cisplatin, cyclophosphamide or doxorubicin translated into tumor regression in a mouse model for breast cancer (345) . Even though IT approaches based on combination therapies that enhance certain elements of tumor immunity and simultaneously inhibit others, most notably CTLA-4 blockade, give more encouraging results than single approaches, finding the optimal clinical strategy for IT has in many cases proved elusive (346) . Perhaps the key is that it is necessary to think and examine the local intratumoral events rather than what happens systemically. In many cases, the impact of therapies on the tumor microenvironment was simply not investigated.
CONCLUSIONS
This review has summarized some of the most recent developments in cancer therapies. We have tried to focus on effects of conventional and novel therapies on the tumor microenvironment and how this might influence tumor immunity. What is obvious is that therapies must affect the tumor microenvironment if they are to be effective and these changes may be used as a barometer of efficacy. It is also evident that the fact that most IT strategies will remain disappointing if used on their own and the key to improved cure rates will most likely lie in combination therapies that treat tumors for what they are, namely the product of a development process that has used many mechanisms to escape from normal growth control and immune recognition. Every therapy should be chosen with great care because they are based on a variety of concepts, some of which might be mutually antagonistic when used in combination. Finally, we suggest that the tumor microenvironment presents several distinct integrated profiles of gene expression and cell content that incorporate physiological changes and host cell content as well as tumor cell characteristics. Recognition of whether the milieu is immunosupportive or immunosuppressive will be critical to our understanding of how to best use therapies that aim to promote tumor immunity. It is also true that, irrespective of the proposed target of a therapy, alterations that are wrought in the tumor microenvironment could lead to unexpected involvement of immune mechanisms that could contribute to tumor cure. This is particularly true if animal models are used that are limited in their applicability to the human situation.
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